Overview
![](/assets/images/picto-drapeau-france-3a76576a5d60a512053b4612ab58dae5.png)
ABSTRACT
Immunotherapy and more particularly vaccines are gaining a role among the various drugs available in oncology. A therapeutic vaccine is composed of one or several proteic or glycoproteic antigens against which the immune system will fight and an adjuvant which amplify the immune response against the former molecules. Today among them two kinds of mineral adjuvants are available: aluminum containing adjuvants, and calcium phosphate.. Their characteristics and mode of action is described hereby.
Read this article from a comprehensive knowledge base, updated and supplemented with articles reviewed by scientific committees.
Read the articleAUTHOR
-
Patrick FRAYSSINET: Director R Urodelia, Saint Lys, France
INTRODUCTION
Over the course of the 20th century, vaccines have become the most effective tool for preventing infectious diseases and allergies. They are used to prevent two of the most common cancers of infectious origin in humans: liver cancer and uterine cancer. Other cancers are not of infectious origin, but therapeutic vaccines are currently being studied in oncology to treat cancers that have already occurred. These vaccines are possible because cancer cells produce abnormal proteins which, under normal conditions, trigger an immune response that eliminates these cells.
Treating cancer by stimulating the immune system is not a new idea. Very advanced cancers that regressed spontaneously have been known since ancient times. At the beginning of the 20th century, William Cole, an American surgeon, injected bacterial extracts into connective tissue cancer tumors (sarcoma), triggering a non-specific inflammatory reaction in the tumor cells with very significant hyperthermia, and achieving results largely comparable to those obtained today with heavy chemotherapy. More recently, cancers of the bladder epithelium have been washed with a solution containing inactivated bacillus Koch (BCG) to trigger a cellular immune response against the cancer cells.
Today, many techniques exist to activate the immune system, many of them involving tissue engineering techniques. We will focus on classical vaccine techniques, namely the injection of one or more proteins or glycoproteins specific to the agent to be eliminated, accompanied by an adjuvant agent that amplifies the immune response against the preceding compounds. In this article, we describe the contribution of inorganic vaccine adjuvants to cancer immunotherapy.
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
![](/assets/images/logo-eti-286623ed91fa802ce039246e516e5852.png)
The Ultimate Scientific and Technical Reference
KEYWORDS
state of the art | Adjuvants | cancer vaccine | health |
CAN BE ALSO FOUND IN:
This article is included in
Healthcare technologies
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Mineral adjuvants for oncology vaccines
Bibliography
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
![](/assets/images/logo-eti-286623ed91fa802ce039246e516e5852.png)
The Ultimate Scientific and Technical Reference